ORLANDO, FL /Send2Press Newswire/ — Global Medical Research, LLC (www.gmrllc.com), a Central Florida-based company dedicated to developing and commercializing intellectual properties that address problems in the biomedical field, today announced the launch of breakthrough technology designed to prevent post surgical adhesions. GMR’s Internal-Tissue Engineered Membrane Product (i-TEMP(tm)), is now poised for advanced phase animal testing to support the expectations of a broad spectrum of uses.
The base technology has been in development for several years at the University of North Texas Health Science Center under the direction of Dr. S. Dan Dimitrijevich, Director of the Tissue and Cell and Tissue Engineering Division of the Cardiovascular Research Institute. With the acquisition of exclusive Worldwide Licensing Rights for i-TEMP(tm), GMR has also undertaken the financial responsibility for the commercialization steps that include process development and product testing.
In order to maintain a proprietary position, information about the device is limited, but what is evident from the company’s research is that the efficacy in prevention of adhesions is greater than ninety percent. In addition, i-TEMP(tm) has an excellent shelf life, is easy to handle, can be delivered laproscopically, and is completely bio-absorbed after application. GMR also maintains that the materials that would be used for the manufacture of i-TEMP(tm) have been approved by the FDA for use in other biomedical devices that are FDA approved and currently being used in humans.
While the research and development work continues to be performed by Dr. S. Dan Dimitrijevich and his team at UNTHSC, all contractual negotiations and other aspects of commercialization are conducted at GMR’s corporate headquarters in Winter Park, Florida.
i-TEMP(tm) is anticipated to save billions of dollars in health care costs associated with re-do surgeries to resolve Adhesion Related Disorders (ARD) which result in extended hospital stays, and could possibly reduce some of the 2,500 adhesion related deaths each year. i-TEMP(tm) is expected to improve the quality of life for a multitude of surgical patients that include an increasing number of women undergoing hysterectomies, C-sections or suffering from endometriosis.
GMR’s Medical Advisory Board currently includes 5 highly qualified individuals and is expected to add two additional members. Presently the Board is chaired by Dr. Kevin Accola (Cardiovascular Surgeon, Founder/Member). The other Medical Advisory Board Members are: Dr. Dan Dimitrijevich (Director of Research/Inventor/Founder), Dr. Joseph Allgeier (Director of Medical Education at Florida Hospital), Dr. Albert Olivencia-Yurvati (Associate Professor of Cardiovascular Surgery, UNTHSC), and Dr. David Wiseman (founder of the International Adhesion Society and a recognized leader in the testing and evaluation of adhesion prevention).
GMR is maintaining close contact and discussions with its regulatory consultants in order to assure that all FDA criteria are being observed. GMR has been approached by hedge funds, distributors, manufacturers, proposing partnerships, the sale of the devise and/or joint ventures to manufacture and distribute what is likely to be millions of i-TEMP(tm)s annually.
For additional information regarding the severity of ARD visit the following web sites: www.adhesions.org or www.adhesions.org.uk.
More information about Global Medical Research, LLC
Mr. Michael Garfield, CEO
Mr. Harvey Berger, Exc. VP / Dir. Of Oper.
of Global Medical Research
News issued by: Global Medical Research, LLC
# # #
Original Story ID: (122) :: 2005-02-0225-004
Original Keywords: i-TEMP, Global Medical Research, LLC, adhesions, surgery, obgyn, anti-adhesions, biotech, adhesion prevention, medical devices, dr. dan dimitrijevich, Michael Garfield, Harvey Berger, Kevin Accola, President Clinton, Bill Clinton Surgery, procedure Global Medical Research, LLC
News Source: Global Medical Research, LLC